

# Frequency and dosing of urate-lowering therapy in patients with CKD 3 - baseline data of the German Chronic Kidney Disease (GCKD) Study cohort



Markus Heisterkamp\*, Stephanie Titze², Johan M. Lorenzen\*, Kai-Uwe Eckardt², Anna Köttgen,³ Martin Busch⁴, and Jan T Kielstein\* for the **GCKD-Study investigators** 

\*Department of Nephrology and Hypertension, Hannover Medical School, Germany, <sup>2</sup>Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany, <sup>3</sup>Renal Division, Department of Medicine, University Hospital Freiburg, Freiburg Germany, <sup>4</sup>Department of Internal Medicine III, University of Jena, Jena, Germany

## Background and aims


- > up to 80 % of patients with CKD exhibit elevated urate levels
- retrospective data and small prospective studies suggest that progression of CKD can be delayed and proteinuria lowered by urate-lowering therapy (ULT)
- dose adjustment of ULT, i.e. allopurinol is required in CKD
- Study aims: i) determine the frequency of ULT in patients with CKD stage 3, ii) the dosing of ULT, and iii) the efficacy of ULT

#### Methods

- baseline data and drug prescription pattern were obtained in a 1965 patient subset of the GCKD study by chart review
- the GCKD study is a prospective observational national cohort study that enrolled more than 5000 patients with CKD 3 of various aetiologies and aims to follows them for up to 10 years
- > at the time of enrolment (2011) patients had an estimated glomerular filtration rate (eGFR) of 30-60 mL/min/1.73 m<sup>2</sup>

#### Results


- > 919 (47%) patients had hyperuricemia (>6.5mg/dl) and were not treated by ULT
- among those, 332 (36%) had a urate above 8.5 mg/dl
- > 551 (28.1%) of all patients received ULT:
  - > 519 (94.1%) allopurinol
  - > 18 (3.4%) febuxostat and 21 (3.8%) benzbromarone



- > the median allopurinol dose was 150 mg/d
- > 29.8% of the allopurinol treated patients received 300 mg/d


- > patients without ULT had a median urate of 7.22 [5.98-8.34] mg/dl
- > patients with ULT had a median urate of 6.81 [5.72-6.81] mg/dl
- patients beeing treated with allopurinol had a median urate of 6.89 [5.74- 7.94] mg/dl

#### Urate level and its relation to treatment




In the group of patients on ULT, 376 (68,8%) were above the recommended UAL of 6 mg/dl

#### Allopurinol dose in the GCKD study cohort baseline examination



### Urate level and daily allopurinol dose



#### Conclusions

- > despite the fact that hyperuricemia is frequent in CKD stage 3, only 37% patients were treated
- > treatment largely failed to lower the uric acid level below 6 mg/dl
- > one third of the patients received an allopurinol dose that could lead to accumulation of the main metabolite of allopurinol, i.e. oxipurinol
- > treatment of hyperuricemia in CKD can be improved in both, treatment rate and dose adjustment, further prospective data are needed

136--SP

Acknowledgements: The GCKD Study is funded by the Federal Ministry of Research and Education (BMBF) and the nonprofit KfH Foundation of Preventive Medicine. It is conducted under the patronage of the German Society of Nephrology (DGfN).

